0 Комментарии
0 Поделились
353 Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Новости
- ИССЛЕДОВАТЬ
-
Страницы
-
Группы
-
Мероприятия
-
Статьи пользователей
-
Offers
-
Jobs
-
Форумы
-
Войдите, чтобы отмечать, делиться и комментировать!
-
Hematology Oncology Market: Industry Analysis, Trends, and Future OutlookIntroduction Hematology oncology is a specialized branch of medicine that focuses on the diagnosis, treatment, and management of cancers affecting the blood, bone marrow, and lymphatic system. These malignancies include leukemia, lymphoma, multiple myeloma, and related disorders that require complex, long-term treatment strategies. Over the past decade, hematology oncology has evolved...0 Комментарии 0 Поделились 678 Просмотры 0 предпросмотр
-
U.S. Hematology Oncology Market Growth: Share, Value, Size, Scope, and Insights"Executive Summary U.S. Hematology Oncology Market: Growth Trends and Share Breakdown U.S. Hematology Oncology Market is expected to reach USD 8.86 billion by 2032 from USD 3.39 billion in 2024, growing with a CAGR of 9.2% in the forecast period of 2025 to 2032. In this competitive marketplace, businesses are always in struggle to seek better solutions in terms of product trends, future...0 Комментарии 0 Поделились 251 Просмотры 0 предпросмотр
-
U.S. Hematology Oncology Market Trends: Growth, Share, Value, Size, and Insights"Global Demand Outlook for Executive Summary U.S. Hematology Oncology Market Size and Share U.S. Hematology Oncology Market is expected to reach USD 8.86 billion by 2032 from USD 3.39 billion in 2024, growing with a CAGR of 9.2% in the forecast period of 2025 to 2032. In order to make smart decisions about budgeting, Market strategies, product development, and growth strategies or...0 Комментарии 0 Поделились 388 Просмотры 0 предпросмотр
-
Carfilzomib Market Expands with 7.5% CAGR Driven by Advances in Multiple Myeloma TherapiesAccording to a new report from Intel Market Research, the global Carfilzomib market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.89 billion by 2034, growing at a steady CAGR of 7.5% during the forecast period (2025–2034). This growth reflects the expanding clinical application of Carfilzomib in treating relapsed/refractory multiple myeloma, coupled with rising...0 Комментарии 0 Поделились 586 Просмотры 0 предпросмотр